Effects Of Rituximab On Jak-Stat And Nf-?b Signaling Pathways İn Acute Lymphoblastic Leukemia And Chronic Lymphocytic Leukemia

Basit Öğe Kaydı
dc.authorid260580en_US
dc.authorid107822en_US
dc.authorid106325en_US
dc.contributor.authorDalmızrak, Ayşegül
dc.contributor.authorGünel, Nur Selvi
dc.contributor.authorKaymaz, Burçin Tezcanlı
dc.contributor.authorFahri, Şahin
dc.contributor.authorSaydam, Güray
dc.contributor.authorKosova, Buket
dc.date.accessioned2021-01-25T12:37:36Z
dc.date.available2021-01-25T12:37:36Z
dc.date.issued2019
dc.departmentİstanbul Beykent Üniversitesien_US
dc.description.abstractObjectives: Rituximab is a monoclonal antibody that targets the B-lymphocyte surface antigen CD20. It is used in the treatment of some diseases including B-cell chronic lymphocytic leukemia (B-CLL). There are a lot of data regarding effect of Rituximab on lymphoma cells. But, there is no satisfactory information about the effect of Rituximab on the signaling pathways in leukemia cells. In this study, it was aimed to understand the effect of Rituximab on JAK-STAT and NF-?B signaling pathways in B-cellacute lymphoblastic leukemia (B-ALL) and B-CLL. Material and methods: Apoptotic effect of Rituximab in the TANOUE (B-ALL) and EHEB (B-CLL) cell lines were evaluated by using the Annexin V method. mRNA expression levels of STAT3 and RelA were analysed by quantitative RT-PCR (Q-PCR). Alterations in STAT3 and RelA protein expressions were detected by using a chromogenic alkaline phosphatase assay after Western Blotting. Results: Rituximab had no apoptotic effect on both cell lines. Complement-mediated cytotoxicity was only detected in EHEB cells. mRNA and protein expressions of STAT3 and RelA genes were decreased following Rituximab treatment. Conclusion: Our preliminary results suggest that the use of Rituximab might be effective in B-ALL though both signaling pathways.en_US
dc.identifier.citationTurk J Biochem 2019; 44(4): 499–509en_US
dc.identifier.doi10.1515/tjb-2018-0321
dc.identifier.issn1303-829X
dc.identifier.scopus2-s2.0-85073516743en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.trdizinid340512en_US
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/340512
dc.identifier.urihttps://doi.org/10.1515/tjb-2018-0321
dc.identifier.wosWOS:000489303900011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherTürk Biyokimya Derneğien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.subjectALLen_US
dc.subjectCLLen_US
dc.subjectRituximaben_US
dc.subjectSTAT3en_US
dc.subjectRelAen_US
dc.titleEffects Of Rituximab On Jak-Stat And Nf-?b Signaling Pathways İn Acute Lymphoblastic Leukemia And Chronic Lymphocytic Leukemiaen_US
dc.title.alternativeRituximab’ın Akut Lenfoblastik Lösemi Ve Kronik Lenfositik Lösemide Jak-Stat Ve Nf-?b Sinyal Yolaklarına Etkilerien_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
93 Effects of Rituximab on JAK-STAT and.pdf
Boyut:
890.13 KB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Tıp Fakültesi
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu